Pretreatment CT and
chemoradiation
oesophageal cancer
radiomics
response
Journal
Journal of medical imaging and radiation oncology
ISSN: 1754-9485
Titre abrégé: J Med Imaging Radiat Oncol
Pays: Australia
ID NLM: 101469340
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
07
06
2020
accepted:
21
10
2020
pubmed:
2
12
2020
medline:
6
11
2021
entrez:
1
12
2020
Statut:
ppublish
Résumé
To develop a radiomic-based model to predict pathological complete response (pCR) and outcome following neoadjuvant chemoradiotherapy (NACRT) in oesophageal cancer. We analysed 68 patients with oesophageal cancer treated with NACRT followed by esophagectomy, who had staging 18F-fluorodeoxyglucose ( Median follow-up was 59 months. pCR was achieved in 34 (50%) patients. Five-year RFS, LRC, MFS and OS were 67.1%, 88.5%, 75.6% and 57.6%, respectively. Tumour Regression Grade (TRG) 0-1 indicative of complete response or minimal residual disease was significantly associated with improved 5-year LRC [93.7% vs 71.8%; P = 0.020; HR 0.19, 95% CI 0.04-0.85]. Four sepjmirote pCR predictive models were built for CT alone, PET alone, CT+PET and composite. CT, PET and CT+PET models had AUC 0.73 ± 0.08, 0.66 ± 0.08 and 0.77 ± 0.07, respectively. The composite model resulted in an improvement of pCR predicting power with AUC 0.87 ± 0.06. Stratifying patients with a low versus high radiomic score showed clinically relevant improvement in 5-year LRC favouring low-score group (91.1% vs. 80%, 95% CI 0.09-1.77, P = 0.2). The composite CT/PET radiomics model was highly predictive of pCR following NACRT. Validation in larger data sets is warranted to determine whether the model can predict clinical outcomes.
Identifiants
pubmed: 33258556
doi: 10.1111/1754-9485.13128
doi:
Substances chimiques
Radiopharmaceuticals
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
102-111Informations de copyright
© 2020 The Royal Australian and New Zealand College of Radiologists.
Références
van Hagen P, Hulshof MC, van Lanschot JJ et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012; 366: 2074-84.
Donahue JM, Nichols FC, Li Z et al. Complete pathologic response after neoadjuvant chemoradiotherapy for esophageal cancer is associated with enhanced survival. Ann Thoracic Surg 2009; 87: 392-8; discussion 8-9.
Venkat PS, Shridhar R, Naghavi AO et al. Dose escalated neoadjuvant chemoradiotherapy with dose-painting intensity-modulated radiation therapy and improved pathologic complete response in locally advanced esophageal cancer. Dis Esophagus 2017; 30: 1-9.
Stahl M, Stuschke M, Lehmann N et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005; 23: 2310-7.
Berger AC, Farma J, Scott WJ et al. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol 2005; 23: 4330-7.
Hulshof MCCM, Geijsen D, Rozema T et al. A randomized controlled phase III multicenter study on dose escalation in definitive chemoradiation for patients with locally advanced esophageal cancer: ARTDECO study. J Clin Oncol 2020; 38: 281.
Tixier F, Groves AM, Goh V et al. Correlation of intra-tumor 18F-FDG uptake heterogeneity indices with perfusion CT derived parameters in colorectal cancer. PLoS One 2014; 9: e99567.
Kwee RM. Prediction of tumor response to neoadjuvant therapy in patients with esophageal cancer with use of 18F FDG PET: a systematic review. Radiology 2010; 254: 707-17.
Zhang H, Tan S, Chen W et al. Modeling pathologic response of esophageal cancer to chemoradiation therapy using spatial-temporal 18F-FDG PET features, clinical parameters, and demographics. Int J Radiat Oncol Biol Phys 2014; 88: 195-203.
Marusyk A, Almendro V, Polyak K. Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer 2012; 12: 323-34.
Tan S, Kligerman S, Chen W et al. Spatial-temporal [(1)(8)F]FDG-PET features for predicting pathologic response of esophageal cancer to neoadjuvant chemoradiation therapy. Int J Radiat Oncol Biol Phys 2013; 85: 1375-82.
Gillies RJ, Kinahan PE, Hricak H. Radiomics: images are more than pictures, they are data. Radiology 2016; 278(2): 563-77.
Aerts HJ, Velazquez ER, Leijenaar RT et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun 2014; 5: 4006.
Tixier F, Le Rest CC, Hatt M et al. Intratumor heterogeneity characterized by textural features on baseline 18F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal cancer. J Nucl Med 2011; 52: 369-78.
Lambin P, Rios-Velazquez E, Leijenaar R et al. Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer 2012; 48: 441-6.
Yip C, Davnall F, Kozarski R et al. Assessment of changes in tumor heterogeneity following neoadjuvant chemotherapy in primary esophageal cancer. Dis Esophagus 2015; 28: 172-9.
van Rossum PS, Fried DV, Zhang L et al. The incremental value of subjective and quantitative assessment of 18F-FDG PET for the prediction of pathologic complete response to preoperative chemoradiotherapy in esophageal cancer. J Nucl Med 2016; 57: 691-700.
Ryan R, Gibbons D, Hyland JM et al. Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Histopathology 2005; 47: 141-6.
Delbeke D, Coleman RE, Guiberteau MJ et al. Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0. J Nucl Med 2006; 47: 885-95.
Altazi BA, Fernandez DC, Zhang GG et al. Investigating multi-radiomic models for enhancing prediction power of cervical cancer treatment outcomes. Physica Med 2018; 46: 180-8.
Lambin P, Leijenaar RTH, Deist TM et al. Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol 2017; 14: 749-62.
Hall MA. Correlation-based feature selection for machine learning (PhD Thesis). Department of Computer Science, Waikato University, New Zealand, 1999.
Cortes C, Mohri M. Confidence intervals for the area under the ROC curve. Adv Neural Inf Process Syst 2005; 18: 305-12.
Scalco E, Rizzo G. Texture analysis of medical images for radiotherapy applications. Br J Radiol 2017; 90: 20160642.
van Rossum PSN, Xu C, Fried DV, Goense L, Court LE, Lin SH. The emerging field of radiomics in esophageal cancer: current evidence and future potential. Transl Cancer Res. 2016; 5: 410-23.
Freilich J, Hoffe SE, Almhanna K et al. Comparative outcomes for three-dimensional conformal versus intensity-modulated radiation therapy for esophageal cancer. Dis Esophagus 2015; 28: 352-7.
Blum Murphy M, Xiao L, Patel VR et al. Pathological complete response in patients with esophageal cancer after the trimodality approach: the association with baseline variables and survival-The University of Texas MD Anderson Cancer Center experience. Cancer 2017; 123: 4106-13.
Dittrick GW, Weber JM, Shridhar R et al. Pathologic nonresponders after neoadjuvant chemoradiation for esophageal cancer demonstrate no survival benefit compared with patients treated with primary esophagectomy. Ann Surg Oncol 2012; 19: 1678-84.
Hatt M, Tixier F, Cheze Le Rest C, Pradier O, Visvikis D. Robustness of intratumour (1)(8)F-FDG PET uptake heterogeneity quantification for therapy response prediction in oesophageal carcinoma. Eur J Nucl Med Mol Imaging 2013; 40: 1662-71.